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Hector M. Garcia-Garcia, MD, PHD,† Gerrit-Anne van Es, PHD,† Lorenz Räber, MD,§
ianluca Campo, MD, PHD, Marco Valgimigli, MD, PHD, Keith D. Dawkins, MD,¶
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Objectives This study sought to assess the impact of the SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery) score (SXscore) on clinical outcomes in pa-
tients undergoing percutaneous coronary intervention.
Background The SXscore has been demonstrated to have an ability to predict clinical outcomes in
patients undergoing percutaneous revascularization. Current studies are limited by the relatively
small number of patients in each SXscore group.
Methods Patient-level data from 7 contemporary coronary stent trials were pooled by an indepen-
dent academic research organization (Cardialysis, Rotterdam, the Netherlands). Analysis was per-
formed on a cohort of 6,508 patients treated with drug-eluting stents and who had calculated
SXscores. Clinical outcomes in terms of death, myocardial infarction (MI), repeat revascularization, and
major adverse cardiac events (MACE, a composite of death, MI, and repeat revascularization) were subse-
quently stratiﬁed according to SXscore quartiles: SXscoreQ1 8 (n  1,702); 8  SXscoreQ2 15
n  1,528); 15  SXscoreQ3 23 (n  1,620); and SXscoreQ4 23 (n  1,658).
Results One-year outcomes were available in 6,496 patients (99.8%). At 1-year follow-up, all clinical
outcomes including mortality, MI, repeat revascularization, MACE, and deﬁnite and any stent throm-
bosis were all signiﬁcantly higher in patients in the highest SXscore quartile. Similar trends were ob-
served in a subgroup of 2,093 patients (32.2%) who presented with an ST- or non–ST-segment ele-
vation MI. The rate of MACE among patients with an SXscore 32 and 32 was 24.9% and 14.0%,
respectively (p  0.001). The SXscore was identiﬁed as an independent predictor of all clinical out-
comes including mortality, MACE, and stent thrombosis (p  0.001 for all).
Conclusions This study conﬁrms the consistent ability of the SXscore to identify patients who are
at highest risk of adverse events. (J Am Coll Cardiol Intv 2011;4:645–53) © 2011 by the American
College of Cardiology Foundation
From the *Department of Interventional Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands; †Cardialysis, Rotterdam,
he Netherlands; ‡Department of Cardiac Intensive Care & Interventional Cardiology, Hartcentrum, Hasselt, Belgium;
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646The Synergy Between Percutaneous Coronary Intervention
with Taxus and Cardiac Surgery (SYNTAX) score (SXscore)
is an angiographic scoring system that was developed to
quantify the complexity of coronary artery disease (CAD) in
patients undergoing coronary revascularization (1,2). The score
as initially developed for use in the SYNTAX trial as a means
f bringing together the cardiologist and cardiac surgeon to
tudy, in great detail, the coronary angiogram of patients
elected for enrollment (3). Subsequent analyses, however, have
ndicated that the SXscore can be used to assist in deciding the
ptimal revascularization strategy in patients with complex
AD (3,4), while also identifying those patients treated by
ercutaneous coronary intervention (PCI) who are at highest
isk of adverse cardiac events (3–14). This ability to risk stratify
atients has been evaluated in numerous studies, which include
hose with an all-comers design (8–10), and those more specifi-
cally enrolling patients with multi-
vessel disease (5,6), complex CAD
(triple-vessel and/or left main dis-
ease) (3,12–14), or those presenting
with ST-segment elevation myo-
cardial infarction (STEMI) (11).
Importantly, the SXscore has con-
sistently been identified as an inde-
pendent predictor of major adverse
cardiac events (MACE) and/or
mortality at follow-up ranging be-
tween 1 and 5 years (5–13).
These assessments of the SX-
score are limited however by the
relatively small number of pa-
tients in each SXscore tertile,
which have ranged from approx-
imately 200 to 700 patients
(5,8). In an effort to overcome
these limitations, the present
study pooled patient-level data
from 7 contemporary coronary
tent trials (3,15–20) where the SXscore was available,
hereby enabling a more precise evaluation of the benefit of
alculating the SXscore in patients treated by PCI.
ethods
Study design and patient population. We identified 7 con-
emporary coronary stent trials for which the SXscore was
vailable (3,15–20): SIRTAX (Sirolimus-Eluting Stent
§Department of Interventional Cardiology, Bern University Hospital, Bern, Switzer-
land; Department of Interventional Cardiology, Cardiovascular Institute, University
of Ferrara, Ferrara, Italy; and ¶Boston Scientific, Natick, Massachusetts. Dr. Garg has
received honorarium fromMedtronic. Dr. Valgimigli reports research grants for lecturers
and advisory boards: Iroko, Eli Lilly, Medtronic, and honoraria for lecturers and/or
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
SXscore  Synergy Between
Percutaneous Coronary
Intervention with Taxus and
Cardiac Surgery score
TVR  target vessel
revascularizationadvisory boards: Cordis, Medtronic, Abbott, Eisai, Merck, AstraZeneca, MedCo, and
M
2ompared With Paclitaxel-Eluting Stent for Coronary
evascularization) trial, LEADERS (Limus Eluted From a
urable Versus Erodable Stent Coating) trial, RESOLUTE
Resolute All Comers) trial, ARTS II (Arterial Revascular-
zation Therapies Study II), SYNTAX, STRATEGY (Sin-
le High-Dose Bolus Tirofiban and Sirolimus-Eluting
tent Versus Abciximab and Bare-Metal Stent in Myocar-
ial Infarction) trial, and MULTISTRATEGY (Multi-
enter Evaluation of Single High-Dose Bolus Tirofiban
ersus Abciximab With Sirolimus-Eluting Stent or Bare-
etal Stent in Acute Myocardial Infarction) study. De-
ailed individual study design and trial results are available
lsewhere (3,15–20). In brief, all studies included patients
ith obstructive CAD that was amendable to coronary stent
mplantation, with drug-eluting stents used exclusively in all
ut 2 studies. Study inclusion criteria were deliberately
eterogeneous ranging from an all-comers design (15–17),
o studies only recruiting patients with complex CAD
3,18), or only those with STEMI (19,20). A summary of all
tudies, including pertinent inclusion and exclusion criteria,
tudy stents, study procedures, and dual antiplatelet therapy
egimes are shown in Online Table 1. All studies complied
ith the Declaration of Helsinki and were approved by the
thical review board in each institution. All patients pro-
ided written, informed consent for participation in the
ndividual studies.
After identification of appropriate studies, the principal
nvestigators of each study were subsequently contacted and
ndividual patient data were requested on a broad range of
ore baseline clinical variables, procedural results, and clin-
cal outcomes at 1-year follow-up. Clinical outcomes in-
luded data on death, myocardial infarction (MI), any
epeat revascularization (either PCI or coronary artery
ypass graft [CABG]), and stent thrombosis (ST). Death
nd MI were available from all studies, whereas any repeat
evascularization was only available from 4 studies: ARTS II,
YNTAX, RESOLUTE, and LEADERS. Of the remaining 3
tudies, 2—STRATEGY and MULTISTRATEGY—
eported only clinically indicated target vessel revasculariza-
ion (TVR) (19,20), whereas 1—SIRTAX—reported clin-
cally and nonclinically driven target lesion revascularization
nd TVR (16). Data for ST was available from all studies. A
ummary of individual trial endpoints is shown in Online
able 2.
Patient-level-based data were subsequently transferred to
n independent academic research organization (Cardialy-
is, Rotterdam, the Netherlands), where they were merged
erumo. Dr. Dawkins is an employee of Boston Scientific. Dr. Windecker received
esearch grants Abbott, Biosensors, Biotronik, Cordis, Boston Scientific, and Medtronic.
ll other authors have reported that they have no relationships to disclose. JohnHirshfeld,
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647with a database containing the calculated SXscore and its
components. Data from each trial were recoded by research-
ers (S.G., M.S., and T.d.V.), and finally, 2 researchers
(S.G., P.W.S.) analyzed and interpreted the data.
SYNTAX score. The SXscore for each patient was calculated
y scoring all coronary lesions with a diameter stenosis
50%, in vessels 1.5 mm, using the SXscore algorithm,
hich is described in full elsewhere (1,2) and is available on
he SXscore Website (21). In the SYNTAX, LEADERS,
nd RESOLUTE studies, all angiographic variables re-
uired to calculate the SXscore were recorded prospectively
y a team of 2 core laboratory analysts (Cardialysis)
3,15,17). In contrast, the SXscore in the SIRTAX, ARTS
I, STRATEGY, and MULTISTRATEGY studies was
alculated retrospectively by individual teams made up of 2
esearchers (S.G., G.S., C.G., or M.V.) (16,18–20). Of
ote, at the time of the calculation, all investigators were
linded to clinical data, clinical presentation, and outcomes.
n the event of disagreement, the opinion of a third analyst
as sought, and the final decision was established by
onsensus. Core laboratory analysts and researchers have
een shown on 2 occasions to have a similar degree of
ntraobserver variability (2,22).
The initial description of the SXscore calculation did not
nclude patients presenting with STEMI or those with
estenotic lesions. Patients with occluded infarct-related
rteries were subsequently scored as occlusions of unknown
uration in a similar manner as any chronically occluded
rtery. Similarly, patients with lesions due to restenosis or
n-stent restenosis were scored in the same manner as if the
esion were a de novo lesion. Although this methodology
as not described in the original description of the SXscore,
t has previously been applied to other all-comers and
TEMI populations (8–11).
Clinical endpoints and deﬁnitions. The primary endpoint of
this pooled analysis was all-cause mortality at 1-year follow-
up. The secondary endpoints included MACE, a composite
of death, MI, and any repeat revascularization; a combined
safety endpoint of death and MI; and the individual
endpoints of MI, repeat revascularization (PCI or CABG),
and stent thrombosis. In patients presenting with an MI,
clinically indicated TVR is also reported.
Complete definitions are available in the individual study
publications (3,15–20). Deaths from all causes are reported.
As indicated in Online Table 3, there was a wide variation
in the definition of MI between studies that reflects the
heterogeneous study inclusion criteria, the variations in
study design, and the different periods during which studies
were performed. As all clinical events from each individual
trial were adjudicated by independent clinical event com-
mittees, no attempt was made to readjudicate MI events in the
different trials to compensate for the differences in individual
definition of MI. Therefore, all MIs reported in the current
study are as per individual protocol definitions. All repeatrevascularization procedures were reported. The definitions of
target lesion revascularization and TVR, and the criteria for
a clinically driven revascularization used in the 5 studies
reporting these outcomes (15–17,19,20) are provided in
Online Table 2. All studies apart from the SYNTAX study
reported ST defined according to the Academic Research
Consortium definitions (23).
Statistical analysis. All patients with a calculated SXscore
ere included in the analysis. All variables were stratified
ccording to SXscore quartiles. Discrete data were summa-
ized as percent (frequencies), whereas continuous data were
xpressed as mean  SD. Testing for (linear) trends was
one by using generalized linear models with SYNTAX
lass as a covariable for continuous variables and the
ochran-Armitage test for trends in categorical data. The
istribution of the SXscore was assessed for normality using
he Kolmogorov-Smirnov test. Clinical outcomes are pre-
ented separately for all patients, those presenting with an
I (STEMI or non-STEMI), and those patients with an
Xscore 32, which was the highest SXscore tertile in the
YNTAX study (3). Survival curves were constructed for
ime-to-event variables using Kaplan-Meier estimates and
ompared by the log-rank test. Patients lost to follow-up
ere considered at risk until the date of last contact, at
hich point they were censored. A Cox multivariate model
Figure 1. Distribution of the SYNTAX Scores Among the 6,508 Patients
Enrolled in the Study
Histograms of the SYNTAX (Synergy Between Percutaneous Coronary Inter-
vention With Taxus and Cardiac Surgery) score with a superimposed nor-
mal curve. The score distribution is skewed to the right, and not normally
distributed.
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648was performed using the covariates sex, age greater than 65
years, diabetic status, urgency of procedure, SXscore, and
use of a first-generation drug-eluting stent. A p value of
0.05 was considered significant, and all tests were 2-tailed.
Data were analyzed with SAS (version 9.2, SAS Institute,
Inc., Cary, North Carolina).
Results
The SXscore was available in 6,508 of 7,639 patients (85.2%)
enrolled in the 7 individual studies. The main reasons for
absent SXscores were missing baseline angiograms, the pres-
ence of prior surgical revascularization, or treatment with
bare-metal stents. In total, the SXscore ranged from 0 to 83,
with a mean  SD of 16.7  11.1 and a median of 15
(interquartile range: 8 to 23). The distribution of the SXscore
is shown in Figure 1; the score was not normally distributed
(Kolmogorov-Smirnov test p  0.05). In this analysis, the
6,508 patients were divided according to their SXscore into
quartiles defined as: SXscoreQ1 8 (n  1,702), 8  SX-
coreQ2 15 (n  1,528); 15  SXscoreQ3 23 (n  1,620);
Table 1. Baseline Clinical Characteristics Stratified According to SYNTAX
Variable
SXscore <8
(n  1,702)
8 < S
(n
Baseline characteristics
Male 73.7 (1,254) 74.3 (
Age, yrs 62.2 10.7 62
Body mass index, kg/m2 27.6 4.3 27
Risk factors
Previous MI 28.9 (423/1,464) 29.3 (
Diabetes 18.7 (316/1,689) 20.4 (
Hypertension 68.7 (1,159/1,686) 68.1 (
Hypercholesterolemia 65.4 (1,110/1,681) 63.1 (
Family history of ischemic heart
disease
40.6 (396/976) 35.8 (
Current smoker 36.0 (510/1,417) 33.6 (
Peripheral vascular disease 5.9 (57/964) 7.2 (
Previous PCI 31.8 (468/1,470) 24.8 (
Previous stroke 3.9 (34/879) 2.9 (
Creatinine clearance, ml/1.73 m2 95.0 42.4 94
Creatinine 200 mol/l 0.6 (8/1,392) 1.0 (
Ejection fraction 58.2 11.0 56
SYNTAX score 5.0 2.2 11
Indication for treatment
Stable angina 38.5 (656) 36.5 (
Unstable angina 19.4 (330) 17.1 (
ST-segment elevation MI 18.4 (314) 23.3 (
Non–ST-segment elevation MI 15.3 (261) 15.1 (
Silent ischemia 9.9 (62/625) 9.7 (
Values are % (n), mean SD, or % (n/N).
MImyocardial infarction; PCI percutaneous coronary intervention; SXscore SYNTAX scoreXscoreQ4 23 (n  1,658).Baseline angiographic and procedural characteristics. Base-
ine clinical, angiographic, and procedural characteristics of the
tudy population, stratified according to SXscore quartiles, are
hown in Tables 1 and 2. Table 2 demonstrates that indicators
f lesion complexity, such as an ostial lesion, a total occlusion,
nd the presence of a bifurcation, were all significantly more
ommon in the highest SXscore quartile, reflecting the higher
alculated SXscore for these lesions.
Outcomes at 12 months. Clinical outcomes at 12 months,
which were available in 6,496 patients (99.8%) and a subset of
2,093 patients (32.2%) presenting with an STEMI or a non-
STEMI, are shown inTable 3, whereas cumulative survival curves
for all patients and those presenting with an MI are shown in
Figure 2 and Online Figure 1, respectively. Overall, the primary
endpoint of death was significantly higher in the highest SXscore
quartile (1.6% vs. 1.2% vs. 3.2% vs. 4.6%, p  0.001). A similar
trend was noted for all other clinical endpoints, including the
safety composite of death/MI and overallMACE, a composite of
death/MI and repeat revascularization. All clinical outcomes in
patients presenting with an MI, apart from death and cardiac
death, were also significantly worse in those patients in the highest
Quartile
<15
8)
15 < SXscore <23
(n  1,620)
SXscore >23
(n  1,658) p Value
76.1 (1,233) 77.0 (1,276) 0.01
.8 63.7 10.7 66.5 10.3 0.001
4 27.5 4.3 27.7 4.6 0.78
54) 30.4 (447/1,471) 33.3 (536/1,611) 0.007
19) 24.5 (395/1,611) 29.2 (483/1,653) 0.001
,516) 69.8 (1,120/1,605) 71.4 (1,177/1,648) 0.06
11) 65.8 (1,054/1,602) 68.1 (1,119/1,642) 0.04
1) 35.7 (353/988) 28.5 (338/1,188) 0.001
11) 32.3 (448/1,385) 22.9 (341/1,489) 0.001
) 7.0 (69/991) 9.1 (111/1,221) 0.007
69) 19.1 (285/1,492) 12.8 (208/1,623) 0.001
) 4.4 (43/974) 7.0 (87/1,240) 0.001
.1 89.7 32.9 84.9 31.7 0.001
7) 0.7 (11/1,487) 1.8 (28/1,576) 0.004
.7 56.0 12.6 55.5 13.4 0.001
7 18.3 2.3 31.8 8.3 0.001
35.6 (576) 42.1 (698) 0.07
19.8 (321) 24.5 (406) 0.001
22.3 (362) 14.6 (242) 0.005
12.1 (196) 7.9 (131) 0.001
) 9.8 (79/809) 8.6 (100/1,157) 0.37
X Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.Score
Xscore
 1,52
1,136)
.8 10
.9 4.
397/1,3
310/1,5
1,032/1
954/1,5
312/87
441/1,3
62/865
339/1,3
24/830
.0 35
14/1,36
.2 11
.4 1.
558)
262)
356)
231)
61/630SXscore quartile.
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649The rate of ST followed the same trend as other
clinical outcomes, with the highest rate noted in SX-
scoreQ4. Of note, rates of ST were higher in all quartiles
or patients presenting with an MI compared with the
ull patient cohort.
Clinical outcomes in patients with a SYNTAX score above and
below 32. In the current analysis, 9.3% of patients had an
SXscore32. The clinical outcomes of patients with an SXscore
above and below 32 are shown in Table 4, whereas cumulative
survival curves are shown in Online Figure 2. All events were at
least 1.5more common in patients with an SXscore32 (p
0.001 for all), and overall approximately one-quarter of patients in
this high-risk group experienced an event (death, MI, or repeat
revascularization) within 12 months.
Multivariable analysis. The results of the Cox multivariable
nalysis are shown in Table 5. Following adjusting of the
onfounding factors: age 65 years, sex, urgency of proce-
ure, diabetic status, and use of a first-generation drug-
luting stent, the SXscore remained an independent predic-
or of clinical outcomes such as mortality, MACE, and ST
Table 2. Baseline Lesion and Procedural Characteristics Stratified Accordi
Variable
SXscore <8
(n  1,702)
8 < SX
(n 
Extent of disease
Number of disease lesions 1.4 0.7 2.3
1-vessel disease 69.6 (1185) 30.6 (46
2-vessel disease 25.7 (437) 49.6 (75
3-vessel disease 2.7 (46) 17.2 (26
Lesion location
Left main stem 0.4 (7) 3.8 (58
Right coronary artery 47.9 (816) 58.5 (89
Circumﬂex artery 33.9 (577) 49.3 (75
LAD artery 47.2 (803) 72.6 (1,
Proximal LAD involvement 8.0 (136) 19.9 (30
All de novo lesions 92.7 (1,304/1,407) 93.9 (1,
Lesion characteristics
1 bifurcation lesion 18.9 (322) 48.7 (74
1 trifurcation lesion 0.5 (9) 2.0 (31
1 ostial lesion 1.8 (30) 3.9 (60
1 occlusion 7.9 (135) 21.1 (32
1 tortuous lesion 15.0 (256) 29.1 (44
1 lesion 20 mm 12.3 (209) 28.1 (43
1 calciﬁed lesion 3.1 (52) 11.8 (18
1 lesion with thrombus 5.2 (88) 6.3 (97
Procedural characteristics
Number of stents implanted 1.7 1.1 2.2
Total stent length, mm 24.6 15.3 36.3
100 mm of stent implanted 0.4 (4/1,086) 2.1 (20
Post-procedural hospital stay, days 2.1 2.8 2.5
Values are mean SD, % (n), or % (n/N).
LAD left anterior descending artery; other abbreviations as in Table 1.any and definite).iscussion
This study is the largest assessment of the SXscore in
patients treated with PCI, and it confirms the ability of the
SXscore to identify patients who are at highest risk of
adverse events, irrespective of clinical presentation.
Several risk models have been developed for patients
undergoing PCI; however, few, if any, have become embed-
ded into regular clinical practice. Most of these risk models
including the Mayo Clinic Risk Score, the EuroSCORE
(European System for Cardiac Operative Risk Evaluation),
and the National Cardiovascular Database Registry Cath-
PCI risk score use a selection of clinical variables that have
been identified as independent predictors of adverse out-
come in those treated by PCI (24–30).
In contrast, the SXscore assesses the angiographic com-
plexity of CAD and does not include any clinical variables in
its calculation. The score was initially developed for the
SYNTAX trial (3) to ensure the angiograms of patients
selected for enrollment were appropriately scrutinized by
SYNTAX Score Quartile
<15
)
15 < SXscore <23
(n  1,620)
SXscore >23
(n  1,658) p Value
3.0 1.2 4.1 1.6 0.001
15.4 (250) 6.1 (101) 0.001
42.4 (687) 24.9 (413) 0.11
40.4 (655) 66.7 (1,106) 0.001
6.2 (100) 21.1 (350) 0.001
67.4 (1,092) 80.5 (1,335) 0.001
63.4 (1,027) 81.7 (1,354) 0.001
88.7 (1,437) 93.8 (1,555) 0.001
34.8 (563) 60.3 (1,000) 0.001
88) 95.3 (1,432/1,503) 96.5 (1,547/1,603) 0.001
60.9 (986) 71.6 (1,187) 0.001
3.2 (52) 8.0 (132) 0.001
4.2 (68) 8.1 (134) 0.001
33.1 (537) 42.9 (712) 0.001
41.6 (674) 62.7 (1,039) 0.001
46.0 (745) 66.9 (1,109) 0.001
21.1 (342) 43.6 (723) 0.001
6.7 (108) 6.2 (103) 0.18
2.9 2.0 4.0 2.3 0.001
51.7 35.0 75.7 46.3 0.001
9.7 (104/1,075) 24.9 (312/1,253) 0.001
2.8 3.3 3.8 6.3 0.001ng to
score
1,528
 1.0
7)
8)
3)
)
4)
4)
110)
4)
303/1,3
4)
)
)
3)
4)
0)
0)
)
 1.5
 24.0
/966)
 2.7members of the Heart Team, thereby ensuring patients
yocardi
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650entered the appropriate arm of the trial. At the time of its
development, it was hypothesized that the SXscore might
help in identifying patients at highest risk of adverse events
(1). Subsequent evaluations of the SXscore have confirmed
this (3–14); however, studies have been hampered by
relatively modest-sized patient cohorts, which for the pur-
pose of analysis have been further subdivided into tertiles.
Of note, the largest published assessment of the SXscore to
date in patients treated with PCI, reported outcomes in
2,033 patients, with only 698 patients in the largest tertile
(8). Importantly, the current pooled analysis has demon-
strated findings consistent with previous evaluations of the
SXscore, and to its strength, over 1,500 patients were
present in each subgroup, alleviating some of the earlier
concerns and ensuring robustness of the results. Further-
more, the identification of the SXscore as an independent
predictor of clinical outcomes, including mortality MACE
and ST, also provides further evidence to support the more
routine use of the SXscore in the assessment of patients
undergoing PCI.
This ability to identify patients at higher risk of adverse
events has important clinical and research implications.
From a clinical point of view, it enables physicians to more
adequately inform or counsel their patients regarding the
Table 3. Clinical Outcomes at 1-Year Follow-Up Among All Patients and Th
Variable
SXscore <8
(n  1,702)
8 < S
(n 
All patients
Death 1.6 (28) 1.2
Cardiac death* 0.8 (12/1,567) 0.8
MI 2.9 (50) 3.2
Any repeat revascularization† 7.7 (94/1,215) 8.7
Death or MI 4.3 (73) 4.1
Death/MI or repeat revascularization† 10.8 (131/1,215) 11.4
ARC any stent thrombosis‡ 1.3 (22/1,692) 1.9
ARC deﬁnite stent thrombosis‡ 0.6 (10/1,692) 1.2
Patients presenting with MI§ n  575 n
Death 2.4 (14) 1.7
Cardiac death* 0.9 (4/440) 1.1
MI 1.7 (10) 2.9
Any repeat revascularization† 7.3 (21/287) 9.4
Clinically indicated target vessel
revascularization
2.8 (16) 4.4
Death or MI 4.0 (23) 4.3
Death/MI or repeat revascularization† 9.8 (28/287) 12.3
ARC any stent thrombosis 1.4 (8) 2.2
ARC deﬁnite stent thrombosis 0.7 (4) 1.4
Values are % (n) or % (n/N). *Cardiac death not available in the STRATEGY andMULTISTRATEGY stud
‡Any stent thrombosis or definite stent thrombosis defined according toARCwas not available in th
MI were excluded from the SYNTAX and ARTS II studies.
ARC  Academic Research Consortium; ARTS II  Arterial Revascularization Therapies Study II
Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction; SIRTAX  Sirolimus-El
High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Mpotential risk of adverse events and in the choice of 1revascularization procedure (CABG vs. PCI). Conse-
quently, this should act as a trigger for more aggressive
secondary preventive therapy, and lifestyle modification in
those at highest risk, as well as close clinical monitoring of
recurrent signs or symptoms of ischemia. Importantly, the
present data also indicate that the SXscore is an indepen-
dent predictor of ST, which speculatively might help iden-
tify those patients who would benefit most from assessment
of platelet function together with more intensive, tailored
and/or prolonged antiplatelet therapy. In clinical research,
the ability to identify a population of patients with a
particular anticipated event rate might help determine
inclusion criteria for the design of more appropriately
powered studies.
Previous studies that have assessed the SXscore and
included a surgical treatment arm have concluded that
SXscores 32/34 are the threshold above which patients
fare better with CABG (3,4). In the present study, a
one-tenth of the cohort had an SXscore over 32, and it is
noteworthy that one-quarter of these patients experienced
an event (death, MI, or repeat revascularization) within 12
months, confirming the poor outcomes associated with very
high SXscores. In comparison, patients in the SYNTAX
study with an SXscore 32, treated with CABG had a
resenting With an MI
<15
6)
15 < SXscore <23
(n  1,617)
SXscore >23
(n  1,651) p Value
3.2 (52) 4.6 (76) 0.001
12) 2.3 (35/1,515) 3.6 (57/1,599) 0.001
3.8 (61) 6.1 (101) 0.001
167) 11.4 (151/1,324) 15.4 (236/1,529) 0.001
6.5 (105) 9.4 (156) 0.001
167) 15.7 (209/1,324) 21.1 (323/1,529) 0.001
48) 3.1 (43/1,373) 4.9 (45/920) 0.001
48) 1.5 (21/1,373) 2.9 (27/920) 0.001
n  558 n  373
5.6 (31) 4.3 (16) 0.006
3.9 (18/456) 2.8 (9/321) 0.005
3.4 (19) 6.4 (24) 0.001
) 12.3 (43/349) 17.6 (50/284) 0.001
6.5 (36) 9.7 (36) 0.001
8.2 (46) 9.9 (37) 0.001
) 18.1 (63/349) 22.5 (64/284) 0.001
5.0 (28) 5.9 (22) 0.001
2.7 (15) 4.3 (16) 0.001
ny repeat revascularization was not available in the SIRTAX, STRATEGY, or MULTISTRATEGY studies.
X study.§Includes ST-segment elevationMI andnon–ST-segment elevationMI. Patientswith acute
STRATEGY  Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With
tent Compared With Paclitaxel-Eluting Stent for Coronary Revascularization; STRATEGY  Single
al Infarction; other abbreviations as in Table 1.ose P
Xscore
1,52
(19)
(11/1,4
(49)
(102/1,
(62)
(133/1,
(28/1,4
(17/1,4
 587
(10)
(5/473)
(17)
(33/351
(26)
(25)
(43/351
(13)
(8)
ies. †A
e SYNTA
; MULTI
uting S-year rate of major adverse cardiovascular and cerebrovas-
With
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651cular events of 10.7% (3). This disparity reiterates the
importance of discussing the most appropriate method of
revascularization, which in this complex subgroup of pa-
tients should ideally be CABG.
The absence of clinical variables has been raised as a
limitation of assessing risk using just the SXscore. Conse-
Figure 2. Kaplan-Meier Cumulative Curves
Kaplan-Meier cumulative curves for (A) death, (B) the composite of death and
events (MACE)—a composite of death, myocardial infarction, and repeat revas
quartiles (Q). SYNTAX  Synergy Between Percutaneous Coronary Intervention
Table 4. Clinical Outcomes at 1-Year Follow-Up Among All Patients With S
Variable SXscore <32 (n  5,895)
Death 2.3 (135)
Cardiac death* 1.5 (85/5,508)
MI 3.8 (222)
Any repeat revascularization† 10.3 (479/4,660)
Death or MI 5.6 (330)
Death/MI or repeat revascularization† 14.0 (652/4,660)
ARC any stent thrombosis‡ 2.3 (122/5,199)
ARC deﬁnite stent thrombosis‡ 1.3 (65/5,199)
Values are % (n) or % (n/N). *Cardiac death not available in the STRATEGY and MULTISTRATEGY stu
‡Any stent thrombosis or definite stent thrombosis defined according to ARC was not available inCI confidence interval; RR risk ratio; other abbreviations as in Tables 1 and 3.quently, several modifications to the SXscore have been
proposed by combining it with risk models using patient
variables such as the ACEF (Value of Age, Creatinine, and
Ejection Fraction) score and EuroSCORE (31,32). Evalu-
ations of these combined scores have shown promising
early results; however, data are limited to initial evalua-
ardial infarction, (C) repeat revascularization, and (D) major adverse cardiac
ation—at 1-year follow-up stratiﬁed according to SYNTAX score (SXscore)
Taxus and Cardiac Surgery.
X Score Above and Below 32
SXscore >32 (n  601) RR (95% CI) p Value
6.7 (40) 2.58 (1.94–3.42) 0.001
5.1 (30/585) 2.81 (2.05–3.86) 0.001
6.5 (39) 1.66 (1.23–2.24) 0.001
18.1 (104/575) 1.76 (1.45–2.14) 0.001
11.0 (66) 1.90 (1.50–2.40) 0.001
24.9 (143/575) 1.85 (1.55–2.20) 0.001
6.8 (16/234) 2.82 (1.75–4.55) 0.001
4.3 (10/234) 3.19 (1.77–5.76) 0.001
ll repeat revascularization was not available in the SIRTAX, STRATEGY, or MULTISTRATEGY studies.
TAX study.myoc
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652tions in small patient populations, and examination in
large robust populations is currently lacking. An exten-
sion to this concept has recently been reported by Chen
et al. (33) who included not only clinical and angio-
graphic variables, but also procedural variables such as the
stenting technique employed. Although these additional
variables were shown to improve the accuracy of risk
prediction, these operator-dependent variables cannot be
reliably predicted before undertaking revascularization,
and therefore, unacceptably, their inclusion moves the
ability to accurately calculate risk to a time point after the
procedure has been completed.
Study limitations. This study is limited by the absence of
CABG comparator arm, and by the limited duration of
ollow-up. Unfortunately, comparisons of the SXscore
ith clinical models such as the EuroSCORE and ACEF
core, and combined scores such as the clinical SYNTAX
core were hindered by the respective absence of recorded
uroSCOREs, and the large number of missing quanti-
ative values for the left ventricular ejection fraction
nd/or creatinine clearance, both of which are needed to
alculate the ACEF and clinical SYNTAX scores.
onclusions
This study confirms the consistent ability of the SXscore to
identify patients who are at highest risk of adverse events,
irrespective of clinical presentation. These results provide
important evidence to support the more routine use of the
SXscore in any patient undergoing percutaneous coronary
revascularization.
Reprint requests and correspondence: Dr. Patrick W. Serruys,
Ba583a, Thoraxcenter; Erasmus Medical Center, ’s-Gravendijkwal
230, 3015 CE Rotterdam, the Netherlands. E-mail: p.w.j.c.serruys@
erasmusmc.nl.
Table 5. Cox Multivariable Analysis
Clinical Outcome
Hazard Ratio for
SYNTAX Score* (95% CI) p Value
Death 1.40 (1.21–1.62) 0.001
MI 1.33 (1.19–1.49) 0.001
Any repeat revascularization 1.29 (1.19–1.39) 0.001
Death or MI 1.33 (1.21–1.46) 0.001
Death, MI, or repeat revascularization 1.30 (1.21–1.40) 0.001
Deﬁnite stent thrombosis 1.64 (1.31–2.05) 0.001
Any stent thrombosis 1.51 (1.28–1.78) 0.001
*After adjustment of confounding factors: age 65 years, sex, urgency of procedure, diabetic
status, and use of a first-generation drug-eluting stent.
Abbreviations as in Tables 1 and 4.REFERENCES
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